AccurEdit Therapeutics builds end‑to‑end in vivo gene‑editing medicines using a proprietary platform that integrates GMP‑grade RNA synthesis, patented base editors and Cas enzymes, and highly efficient delivery systems. Their lead candidate, ART001, achieved over 90% reduction of serum transthyretin (TTR) in four weeks with no detectable off‑target edits, earning FDA Regenerative Medicine Advanced Therapy (RMAT) designation in China. The company focuses on rapid development of systemic CRISPR therapies for serious genetic diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Many genetic diseases are caused by pathogenic mutations that are difficult to treat with conventional small molecules or protein therapies, leading to limited therapeutic options and persistent disease burden.
Solution
AccurEdit Therapeutics creates in vivo CRISPR‑based gene‑editing medicines that directly modify disease‑causing genes inside patients. The platform combines patented base‑editing enzymes, a high‑throughput gRNA screening workflow, and optimized delivery vectors to achieve efficient, systemic editing of target loci. Preclinical data for ART001 demonstrate >90% reduction of serum transthyretin (TTR) within four weeks with no detectable off‑target activity, illustrating the potential for durable disease modification. By streamlining the design‑build‑test cycle, the company aims to accelerate the development of gene‑editing therapeutics for both Chinese and U.S. markets.
Target Audience
Primary customers are pharmaceutical companies and biotech firms seeking to develop gene‑editing therapies for monogenic disorders, as well as clinical research organizations conducting preclinical and early‑phase trials.
Features
- Patented CRISPR base editors that enable precise nucleotide conversions without double‑strand breaks
- Proprietary gRNA discovery platform that screens thousands of candidates to identify high‑efficiency, low‑off‑target guides
- High‑efficiency in vivo delivery system optimized for systemic distribution across multiple tissues
- Integrated safety assessment pipeline that monitors off‑target editing and immunogenicity in preclinical models
- Scalable manufacturing process designed for rapid progression from discovery to clinical-grade product